Should Every Patient with Diabetes ≥ 55 Years of Age Receive an Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin II Receptor Blocker (ARB)?

According to the CDA 2013 Clinical Practice Guidelines, ACE inhibitors or ARBs should be used in all individuals with diabetes who are 55 years of age or older. This recommendation is based on Grade A, Level 1 evidence for those with an additional risk factor or end organ damage, and Grade D, Consensus, for all others. This recommendation is applied differently by different prescribers, particularly for patients that are normotensive and have normoalbuminuria. Participate in this case to explore this issue further based on benefit and risk assessments.

Developed: October 2015

Please Login or Sign Up to gain full access.